Human medicines European public assessment report (EPAR): Ontruzant, trastuzumab, Date of authorisation: 15/11/2017, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Ezmekly, mirdametinib, Date of authorisation: 17/07/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Symtuza, darunavir,cobicistat,emtricitabine,tenofovir alafenamide, Date of authorisation: 21/09/2017, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Piqray, alpelisib, Date of authorisation: 27/07/2020, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Brinsupri, Brensocatib, Date of authorisation: 18/11/2025, Revision: 1, Status: Authorised

List of eligible industry stakeholder organisations

Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Revision: 5, Status: Authorised

Nominations to the Network Portfolio Advisory Group

Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Medicinal products for human use: monthly figures - August 2026